Related Experiment Videos
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions.
K R Chintalacharuvu1, L U Vuong, L A Loi
1Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095, USA. kotec@lifesci.ucla.edu
Clinical Immunology (Orlando, Fla.)
|October 3, 2001
Summary
Researchers engineered novel hybrid antibodies combining Immunoglobulin A (IgA) and Immunoglobulin G (IgG) functions. These engineered antibodies demonstrate unique effector functions and stability, offering new possibilities for antibody therapeutics.
Area of Science:
- Immunology
- Protein Engineering
- Biochemistry
Background:
- Immunoglobulin A (IgA) is crucial for mucosal immunity, existing as polymers bound to secretory component.
- Immunoglobulin G (IgG) is the primary antibody in blood, functioning as a monomer.
- Current antibody engineering often focuses on enhancing specific effector functions.
Purpose of the Study:
- To create hybrid antibodies merging IgA and IgG effector functions.
- To investigate the properties and stability of these novel IgA/IgG hybrid antibodies.
- To explore new strategies for engineering antibodies with combined functionalities.
Main Methods:
- Production of IgA2/IgG1 hybrid antibodies by engineering the heavy chain.
- Analysis of polymer formation, J chain incorporation, and polymeric Ig receptor binding.
- Assessment of complement activation, FcgammaRI and Protein A binding.
- Evaluation of in vivo half-life and avidity for murine FcRn.
- Investigation of antibody stability under varying pH conditions by replacing Cgamma1 with Calpha1.
Main Results:
- Successfully produced IgA2/IgG1 hybrid antibodies exhibiting properties of both IgA and IgG.
- Hybrid antibodies formed polymers with J chain and bound the polymeric Ig receptor, similar to IgA.
- These proteins activated complement and bound FcgammaRI and Protein A, like IgG.
- Despite containing Cgamma2 and Cgamma3, hybrid proteins showed a short in vivo half-life, correlating with higher avidity for FcRn.
- Antibodies with Calpha1 replacing Cgamma1 demonstrated resistance to extreme pH, indicating enhanced stability.
Conclusions:
- Engineered hybrid antibodies can successfully combine distinct IgA and IgG effector functions.
- The C-terminal region of the IgG heavy chain influences IgA-like polymerization and receptor binding.
- Shortened in vivo half-life in hybrid antibodies may be linked to FcRn avidity.
- Incorporation of Calpha1 can confer enhanced stability to antibody structures.
- These findings provide a foundation for designing antibodies with tailored effector functions and improved stability.